30 Years of Evidence

Take a moment to explore a selection of publications and conference abstracts from around the globe. Find evidence for a wide range of treatment sites including malignant and benign disease, different fractionation schedules and real-time motion synchronization techniques for the CyberKnife® and Radixact®/ TomoTherapy® platforms. We update new papers on a regular basis. See how health professionals are helping to improve patient outcomes.

Treatment of Chordomas and Chondrosarcomas With CyberKnife Robotic Hypofractionated Radiosurgery: A Single Institution Experience

Sallabanda M, Garcia R, Lorenzana L, Santaolalla I, Abarca J, Sallabanda K | Cureus | 2021

Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection

Baumann BC, Nagda SN, Kolker JD, Levin WP, Weber KL, Berman AT, Staddon A, Hartner L, Hahn SM, Glatstein E, Simone CB | J Surg Oncol. | 2016

Phase I Trial of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Ablative Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer

Kunos CA, Sherertz TM, Mislmani M, Ellis RJ, Lo SS, Waggoner SE, Zanotti KM, Herrmann K, Debernardo RL | Front Oncol | 2015

Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11)

Park HJ, Chang AR, Seo Y, Cho CK, Jang WI, Kim MS, Choi C | Anticancer Res | 2015

Stereotactic Radiotherapy in the Retreatment of Recurrent Cervical Cancers, Assessment of Toxicity, and Treatment Response: Initial Results and Literature Review

Pontoriero A, Iatì G, Aiello D, Pergolizzi S | Technol Cancer Res Treat | 2016

Long-term results of robotic radiosurgery for non brachytherapy patients with cervical cancer

Morgenthaler J, Köhler C, Budach V, Sehouli J, Stromberger C, Besserer A, Trommer M, Baues C, Marnitz S | Strahlenther Onkol | 2021

CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers

Kataria T, Naga P, Banerjee S, Gupta D, Narang K, Tayal M, Bisht SS | South Asian J Cancer | 2021

Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints

Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, Williamson SK, Mohideen N, Dombrowski JJ, Hong RL, Brachman DG, Linson PW, Kaplan ID. | Int J Radiat Oncol Biol Phys | 2018

Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial

Wang K, Chen RC, Kane B, Medbery CA, Underhill K, Gray JR, Peddada AV, Fuller DB | Int J Radiat Oncol Biol Phys | 2018

5-year Biochemical Outcomes of Stereotactic Body Radiotherapy with Intraprostatic Dose Escalation for Unfavorable Prostate Cancer

Blacksburg SR, Aghdam N, Royce TJ, Burri RJ, Obayomi-Davies O, Mezeckis M, Meier R, Fuller DB, Chen RC, Lanciano RM, Haas JA, Collins SP | Int J Radiat Oncol Biol Phys | 2019

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators | Lancet Oncol | 2019